|
1
|
Towler DA: Arteriosclerosis, bone biology,
and calciotropic hormone signaling: Learning the ABCs of disease in
the bone-vascular axis. J Am Soc Nephrol. 26:243–245.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Vassalle C and Mazzone A: Bone loss and
vascular calcification: A bi-directional interplay? Vascul
Pharmacol. 86:77–86. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Tap L, Kirkham FA, Mattace-Raso F, Joly L,
Rajkumar C and Benetos A: Unraveling the links underlying arterial
stiffness, bone demineralization, and muscle loss. Hypertension.
76:629–639. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Stafford RS, Drieling RL and Hersh AL:
National trends in osteoporosis visits and osteoporosis treatment,
1988-2003. Arch Intern Med. 164:1525–1530. 2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Viaene L, Behets GJ, Heye S, Claes K,
Monbaliu D, Pirenne J, D'Haese PC and Evenepoel P: Inflammation and
the bone-vascular axis in end-stage renal disease. Osteoporos Int.
27:489–497. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zoppellaro G, Faggin E, Puato M, Pauletto
P and Rattazzi M: Fibroblast growth factor 23 and the bone-vascular
axis: Lessons learned from animal studies. Am J Kidney Dis.
59:135–144. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kim JM, Lee WS and Kim J: Therapeutic
strategy for atherosclerosis based on bone-vascular axis
hypothesis. Pharmacol Ther. 206(107436)2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Brandenburg VM, D'Haese P, Deck A, Mekahli
D, Meijers B, Neven E and Evenepoel P: From skeletal to
cardiovascular disease in 12 steps-the evolution of sclerostin as a
major player in CKD-MBD. Pediatr Nephrol. 31:195–206.
2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Fadini GP, Rattazzi M, Matsumoto T,
Asahara T and Khosla S: Emerging role of circulating calcifying
cells in the bone-vascular axis. Circulation. 125:2772–2781.
2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Pieralice S, Vigevano F, Del Toro R,
Napoli N and Maddaloni E: Lifestyle management of diabetes:
Implications for the bone-vascular axis. Curr Diab Rep.
18(84)2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
D'Onofrio L, Maddaloni E and Buzzetti R:
Osteocalcin and sclerostin: Background characters or main actors in
cardiovascular disease? Diabetes Metab Res Rev.
36(e3217)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Figurek A, Rroji M and Spasovski G:
Sclerostin: A new biomarker of CKD-MBD. Int Urol Nephrol.
52:107–113. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
De Maré A, Maudsley S, Azmi A, Hendrickx
JO, Opdebeeck B, Neven E, D'Haese PC and Verhulst A: Sclerostin as
regulatory molecule in vascular media calcification and the
Bone-Vascular Axis. Toxins (Basel). 11(428)2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Leto G, D'Onofrio L, Lucantoni F, Zampetti
S, Campagna G, Foffi C, Moretti C, Carlone A, Palermo A, Leopizzi
M, et al: Sclerostin is expressed in the atherosclerotic plaques of
patients who undergoing carotid endarterectomy. Diabetes Metab Res
Rev. 35(e3069)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Morales-Santana S, García-Fontana B,
García-Martín A, Rozas-Moreno P, García-Salcedo JA, Reyes-García R
and Muñoz-Torres M: Atherosclerotic disease in type 2 diabetes is
associated with an increase in sclerostin levels. Diabetes Care.
36:1667–1674. 2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Saag KG, Petersen J, Brandi ML, Karaplis
AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD and Grauer
A: Romosozumab or alendronate for fracture prevention in women with
osteoporosis. N Engl J Med. 377:1417–1427. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cai L, Huang W and Lin D: Effects of
traditional Chinese medicine Shuxuetong injection on random skin
flap survival in rats. ScientificWorldJournal.
2014(816545)2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Jin X, Shen G, Gao F, Zheng X, Xu X, Shen
F, Li G, Gong J, Wen L, Yang X and Bie X: Traditional Chinese drug
ShuXueTong facilitates angiogenesis during wound healing following
traumatic brain injury. J Ethnopharmacol. 117:473–477.
2008.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Liu X, Qing Wang, Cui Y, Li X and Yang H:
In-depth transcriptomic and proteomic analyses of the hippocampus
and cortex in a rat model after cerebral ischemic injury and repair
by Shuxuetong (SXT) injection. J Ethnopharmacol.
249(112362)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sun ZY, Wang FJ, Guo H, Chen L, Chai LJ,
Li RL, Hu LM, Wang H and Wang SX: Shuxuetong injection protects
cerebral microvascular endothelial cells against oxygen-glucose
deprivation reperfusion. Neural Regen Res. 14:783–793.
2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang X, Xiao B and Hu CL: Study in the
mechanism of Shuxuetong injection on antithrombosis and
thrombolysis. Zhongguo Zhong Yao Za Zhi. 30:1950–1952.
2005.PubMed/NCBI
|
|
22
|
Chen X, Ding X, Liu L, Zhao L, Jiang Z and
Wang X: Effect of Shuxuetong injection on reducing expression of
vascular adhesion molecules in cerebral ischemia and reperfusion
rats. J New Chin Med. 45:128–130. 2013.
|
|
23
|
Wei J, Chen B, Tian Z, Luo K and Deng W:
Effect of Shuxuetong injection on VEGF expression of hind-limb
ischemic vascular disorder in diabetic rats. Zhong Xi Yi Jie He Xin
Nao Xue Guan Bing Za Zhi. 7:1048–1049. 2009.(In Chinese).
|
|
24
|
Zhang Y, Zhou S and Wang B: Effect of
Shuxuetong injection on ET-1, sICAM-1, TNF-α and P-selection in
diabetes mellitus with coronary artery disease. Zhong Xi Yi Jie He
Xin Nao Xue Guan Bing Za Zhi. 6:1271–1272. 2008.(In Chinese).
|
|
25
|
Xi L, Song Y, Wu W, Qu Z, Wen J, Liao B,
Tao R, Ge J and Fang D: Investigation of bone matrix composition,
architecture and mechanical properties reflect structure-function
relationship of cortical bone in glucocorticoid induced
osteoporosis. Bone. 136(115334)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ren H, Liang D, Jiang X, Tang J, Cui J,
Wei Q, Zhang S, Yao Z, Shen G and Lin S: Variance of spinal
osteoporosis induced by dexamethasone and methylprednisolone and
its associated mechanism. Steroids. 102:65–75. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Mori K, Shioi A, Jono S, Nishizawa Y and
Morii H: Dexamethasone enhances In vitro vascular calcification by
promoting osteoblastic differentiation of vascular smooth muscle
cells. Arterioscler Thromb Vasc Biol. 19:2112–2118. 1999.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kirton JP, Wilkinson FL, Canfield AE and
Alexander MY: Dexamethasone downregulates calcification-inhibitor
molecules and accelerates osteogenic differentiation of vascular
pericytes: Implications for vascular calcification. Circ Res.
98:1264–1272. 2006.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tao SC, Yuan T, Rui BY, Zhu ZZ, Guo SC and
Zhang CQ: Exosomes derived from human platelet-rich plasma prevent
apoptosis induced by glucocorticoid-associated endoplasmic
reticulum stress in rat osteonecrosis of the femoral head via the
Akt/Bad/Bcl-2 signal pathway. Theranostics. 7:733–750.
2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
China Animal Management Rule,
documentation No. 55,. 2001, the Ministry of Health of P.R.
China.
|
|
31
|
The National Institutes of Health Guide
for the Care and Use of Laboratory Animals, NIH Publications no.
8023, revised 1978.
|
|
32
|
Duan X, Zhou Y, Teng X, Tang C and Qi Y:
Endoplasmic reticulum stress-mediated apoptosis is activated in
vascular calcification. Biochem Biophys Res Commun. 387:694–699.
2009.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Feng K, Tan J and Chen Y: Treatment of
lower extremity diabetic atherosclerotic obliterans with Shuxuetong
injection. Zhongguo Zhong Xi Yi Jie He Za Zhi. 29:255–257.
2009.PubMed/NCBI(In Chinese).
|
|
34
|
Duan XH, Chang JR, Zhang J, Zhang BH, Li
YL, Teng X, Zhu Y, Du J, Tang CS and Qi YF: Activating
transcription factor 4 is involved in endoplasmic reticulum
stress-mediated apoptosis contributing to vascular calcification.
Apoptosis. 18:1132–1144. 2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Chang JR, Duan XH, Zhang BH, Teng X, Zhou
YB, Liu Y, Yu YR, Zhu Y, Tang CS and Qi YF: Intermedin1-53
attenuates vascular smooth muscle cell calcification by inhibiting
endoplasmic reticulum stress via cyclic adenosine
monophosphate/protein kinase A pathway. Exp Biol Med (Maywood).
238:1136–1146. 2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Yang R, Teng X, Li H, Xue HM, Guo Q, Xiao
L and Wu YM: Hydrogen sulfide improves vascular calcification in
rats by inhibiting endoplasmic reticulum stress. Oxid Med Cell
Longev. 2016(9095242)2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Hao W, Yang R, Yang Y, Jin S, Li Y, Yuan
F, Guo Q, Xiao L, Wang X, Wang F, et al: Stellate ganglion block
ameliorates vascular calcification by inhibiting endoplasmic
reticulum stress. Life Sci. 193:1–8. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Teng X, Song J, Zhang G, Cai Y, Yuan F, Du
J, Tang C and Qi Y: Inhibition of endoplasmic reticulum stress by
intermedin(1-53) protects against myocardial injury through a PI3
kinase-Akt signaling pathway. J Mol Med (Berl). 89:1195–1205.
2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Tian T, Zhao Y, Nakajima S, Huang T, Yao
J, Paton AW, Paton JC and Kitamura M: Cytoprotective roles of ERK
and Akt in endoplasmic reticulum stress triggered by subtilase
cytotoxin. Biochem Biophys Res Commun. 410:852–858. 2011.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Liu H, Li X, Qin F and Huang K: Selenium
suppresses oxidative-stress-enhanced vascular smooth muscle cell
calcification by inhibiting the activation of the PI3K/AKT and ERK
signaling pathways and endoplasmic reticulum stress. J Biol Inorg
Chem. 19:375–388. 2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Rathi A, Ishaq M, Najmi AK and Akhtar M:
Trigonelline demonstrated ameliorative effects in dexamethasone
induced osteoporotic rats. Drug Res (Stuttg). 70:257–264.
2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Qin Z, Li S, Zhang X, Liu G, Gu M, Zhang
N, Liu J, Ji Z, Li K, Han Y and Zhai H: Combination therapy of
wuweizi (Schisandrae Chinensis Fructus) and dexamethasone
alleviated dexamethasone-induced glucocorticoid osteoporosis in
rats with idiopathic pulmonary fibrosis. Biomed Res Int.
2020(6301697)2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Fu L, Wu W, Sun X and Zhang P:
Glucocorticoids enhanced osteoclast autophagy through the
PI3K/Akt/mTOR signaling pathway. Calcif Tissue Int. 107:60–71.
2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Pietrzyk B, Smertka M and Chudek J:
Sclerostin: Intracellular mechanisms of action and its role in the
pathogenesis of skeletal and vascular disorders. Adv Clin Exp Med.
26:1283–1291. 2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Asadipooya K and Weinstock A:
Cardiovascular outcomes of romosozumab and protective role of
alendronate. Arterioscler Thromb Vasc Biol. 39:1343–1350.
2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Alazmi M and Motwalli O: In silico virtual
screening, characterization, docking and molecular dynamics studies
of crucial SARS-CoV-2 proteins. J Biomol Struct Dyn: Aug 7, 2020
(Epub ahead of print). doi: 10.1080/07391102.2020.1803965.
|
|
47
|
Khosla S: Bone diseases: Romosozumab-on
track or derailed? Nat Rev Endocrinol. 13:697–698. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Fontalis A, Kenanidis E, Kotronias RA,
Papachristou A, Anagnostis P, Potoupnis M and Tsiridis E: Current
and emerging osteoporosis pharmacotherapy for women: State of the
art therapies for preventing bone loss. Expert Opin Pharmacother.
20:1123–1134. 2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Chen Z, Pan X, Sheng Z, Yan G, Chen L and
Ma G: Baicalin suppresses the proliferation and migration of
Ox-LDL-VSMCs in atherosclerosis through upregulating miR-126-5p.
Biol Pharm Bull. 42:1517–1523. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Lu X, He W, Yang W, Li J, Han W, Liu Q,
Zhang T, Jiang J, Qin A and Qian Y: Dual effects of baicalin on
osteoclast differentiation and bone resorption. J Cell Mol Med.
22:5029–5039. 2018.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Turk JR, Deaton AM, Yin J, Stolina M, Felx
M, Boyd G, Bienvenu JG, Varela A, Guillot M, Holdsworth G, et al:
Nonclinical cardiovascular safety evaluation of romosozumab, an
inhibitor of sclerostin for the treatment of osteoporosis in
postmenopausal women at high risk of fracture. Regul Toxicol
Pharmacol. 115(104697)2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Ding L, Jia C, Zhang Y, Wang W, Zhu W,
Chen Y and Zhang T: Baicalin relaxes vascular smooth muscle and
lowers blood pressure in spontaneously hypertensive rats. Biomed
Pharmacother. 111:325–330. 2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Liu Y, Jia L, Min D, Xu Y, Zhu J and Sun
Z: Baicalin inhibits proliferation and promotes apoptosis of
vascular smooth muscle cells by regulating the MEG3/p53 pathway
following treatment with ox-LDL. Int J Mol Med. 43:901–913.
2019.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Lv P, Zhang F, Yin YJ, Wang YC, Gao M, Xie
XL, Zhao LL, Dong LH, Lin YL, Shu YN, et al: SM22α inhibits
lamellipodium formation and migration via Ras-Arp2/3 signaling in
synthetic VSMCs. Am J Physiol Cell Physiol. 311:C758–C767.
2016.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Dong LH, Wen JK, Miao SB, Jia Z, Hu HJ,
Sun RH, Wu Y and Han M: Baicalin inhibits PDGF-BB-stimulated
vascular smooth muscle cell proliferation through suppressing
PDGFRβ-ERK signaling and increase in p27 accumulation and prevents
injury-induced neointimal hyperplasia. Cell Res. 20:1252–1262.
2010.PubMed/NCBI View Article : Google Scholar
|
